三磷酸腺苷治疗维拉帕米无效的阵发性室上性心动过速的临床分析  

The Clinical Analysis about Using Adenosine Triphosphate Treatment Paroxysmal Supraventricular Tachycardia Invalid to Verapamil

作　　者：杨庆业[1] 程科云[1] 俎德玲[1] 屠晓鸣[1] 金奇志[1] 高珍艳[1] 郑家胜[1] 

机构地区：[1]衢州市人民医院心内科,浙江衢州324000

出　　处：《中国现代医生》2011年第30期152-153,共2页China Modern Doctor

摘　　要：目的探讨不同剂量的三磷酸腺苷(ATP)对转复维拉帕米无效的阵发性室上性心动过速(PSVT)的疗效及安全性。方法将36例维拉帕米治疗无效的PSVT患者随机分为两组,分别以不同剂量的ATP(第一组:10mg,第二组:20mg),快速静脉推注,若未转复,1min后重复同样剂量再给药1次,观察每组患者的转复时间、有效率、不良反应及转复时伴发的心律失常。结果 10mg初始剂量组的有效率与20mg组比较无统计学差异(P>0.05),小剂量组的复律时间较大剂量组长,而严重心律失常发生率低。结论以小剂量ATP治疗维拉帕米无效的PSVT是安全有效的。Objective To discuss the curative effect and security of different dosage adenosine triphosphate （ ATP ） on converting the verapamil invalid Paroxysmal supraventricular tachycardia （ PSVT ）. Methods Stochastically 35 verapamil treatment invalid PSVT patients were divided into two groups, respectively by different dosage ATP （the first group： 10mg, the second group： 20mg ）, rapidly injected by vein, if had not convert, 1 minute later was redundant the similar dosage to give the medicine again 1 time. The conversion time, effective rate, adverse reaction and the concomitant arrhythmia during the conversion in each group were observed respecitvely. Results 10rag initial monitoring team＇s effectiveness and 20mg the group compared the non-statistics difference （ P 〉 0.05 ）, the small monitoring team＇s conversion time compared large dose group longer, but the severe arrhythmia formation rate was low. Conclusion It is safe and effective in the treatment of invalid PSVT patient to verapamil By small dosage ATP.

关 键 词：阵发性室上性心动过速 三磷酸腺苷 维拉帕米 

分 类 号：R541.7[医药卫生—心血管疾病]